** Brokerage Bernstein raises PT on medical device maker Insulet Corp PODD.O to $335 from $315

** New PT represents 18.5% upside to stock's last close

** Says it maintains "outperform" rating, adding its PT reflects increasing profitability

** Brokerage pointed several growth drivers for co, including integration of its Omnipod insulin pumps with Dexcom's DXCM.O G7 continuous glucose monitor, iOS compatibility with G5 devices, and launch an advanced version of insulin system

** Co's lead product is the Omnipod system, a tubeless, wearable insulin pump

** Co's revenue growth forecast of 17% to 21% is "conservative" and "we like the setup for 2025" - Bernstein

** Brokerage sees potential for growth driven by sales in type 2 diabetes market and expanding profit margins

** Stock has risen ~47% in the past 12 months

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com))